New and Future Focused Therapies for Thyroid Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 15 February 2025 | Viewed by 44
Special Issue Editors
Interests: thyroid cancer; autoimmune thyroid diseases; thyroid irAE; Graves’ disease; thyroid eye disease; molecular basis of thyroid cancer; advanced thyroid cancer; tyrosine kinase inhibitors; medullary thyroid cancer; in vitro cell culture
Special Issues, Collections and Topics in MDPI journals
Interests: thyroid cancer; autoimmune thyroid diseases; thyroid irAE; Graves’ disease; thyroid eye disease; molecular basis of thyroid cancer; advanced thyroid cancer; tyrosine kinase inhibitors; medullary thyroid cancer; occupational health; public health, in vitro cell culture
Special Issues, Collections and Topics in MDPI journals
Interests: thyroid cancer; autoimmune thyroid diseases; thyroid irAE; Graves’ disease; thyroid eye disease; molecular basis of thyroid cancer; advanced thyroid cancer; tyrosine kinase inhibitors; medullary thyroid cancer; in vitro cell culture
Special Issues, Collections and Topics in MDPI journals
Interests: thyroid cancer; immunotherapy; new checkpoint inhibitors; tyrosine kinase inhibitors; PD-1 inhibitors; PD-L1 inhibitors
Special Issue Information
Dear Colleagues,
The incidence of thyroid cancer (TC) is increasing worldwide and new strategy treatments are needed. Treatments against TC are based on the subtypes of TC; differentiated TC usually has a good prognosis, unlike dedifferentiated TC of which the prognosis is not so promising, and require a more challenging approach. Among the approved therapies for TC, for aggressive radioiodine-resistant papillary or follicular TC, multi-targeted kinase inhibitors sorafenib, lenvatinib and cabozantinib have been approved. New compounds acting against specific mutations such as dabrafenib and trametinib have been recently approved for the treatment of BRAFV600E-mutated anaplastic TC.
Lately, new advancements in the molecular field are permitting to choose appropriate and patient-tailored therapy for the treatment of thyroid cancer.
Prof. Dr. Alessandro Antonelli
Dr. Poupak Fallahi
Dr. Silvia Martina Ferrari
Dr. Giusy Elia
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- aggressive differentiated thyroid carcinoma
- anaplastic thyroid cancer
- tyrosine kinase inhibitors
- immunotherapy
- personalized medicine
